Doxorubicin hydrochloride (adriamycin) in irradiated patients with advanced transitional cell carcinoma.
Twenty-five patients with advanced transitional cell carcinoma of the urinary tract were treated with doxorubicin hydrochloride (Adriamycin). Eight evaluable patients who received extensive external irradiation therapy and at least two doses of doxorubicin hydrochloride were studied to assess bone marrow toxicity and possible augmentation of radiation dermatitis. Myelosuppression was similar in both irradiated patients and those who received doxorubicin alone. None of the irradiated patients displayed skin augmentation reactions with doxorubicin. In the dose range used chemotherapy with doxorubicin did not appear to be particularly hazardous in irradiated patients.